Please ensure Javascript is enabled for purposes of website accessibility

Are Hackers Targeting Your Heart?

By Brenton Flynn - Updated Apr 7, 2017 at 12:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Today, fool.com health-care analyst Brenton Flynn looks at the scary reports that hackers may have the ability to remotely "hack" into life-saving medical devices such as pacemakers and insulin pumps and change their settings to deadly levels.

While reports like this make for great sensational headlines, they should be far removed from the investor's psyche. Brenton doesn't think these reports materially affect any company's investment thesis. Instead, in the following video he discusses the true risks for medical-device companies and offers up one company that's designing significantly safer devices.

When it comes to do-or-die businesses, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand-new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

St. Jude Medical, Inc. Stock Quote
St. Jude Medical, Inc.
STJ
Boston Scientific Corporation Stock Quote
Boston Scientific Corporation
BSX
$39.76 (-0.33%) $0.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
334%
 
S&P 500 Returns
117%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.